Pharming Group (NASDAQ:PHAR) Short Interest Down 87.5% in August

Pharming Group (NASDAQ:PHAR) saw a significant decrease in short interest in the month of August. As of August 15th, there was short interest totalling 500 shares, a decrease of 87.5% from the July 31st total of 4,000 shares. Based on an average trading volume of 7,000 shares, the days-to-cover ratio is presently 0.1 days.

Pharming Group Stock Performance

Shares of NASDAQ PHAR traded up $0.32 during mid-day trading on Tuesday, hitting $8.12. The company had a trading volume of 1,282 shares, compared to its average volume of 4,430. Pharming Group has a 12 month low of $6.65 and a 12 month high of $16.71. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.39 and a quick ratio of 2.65. The firm has a market cap of $546.83 million, a P/E ratio of -50.75 and a beta of 0.15. The business’s 50-day simple moving average is $8.11 and its 200-day simple moving average is $9.46.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) earnings per share for the quarter. The firm had revenue of $74.09 million for the quarter, compared to analyst estimates of $71.95 million. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. During the same period in the previous year, the business posted $0.02 EPS. As a group, analysts predict that Pharming Group will post -0.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in shares of Pharming Group (NASDAQ:PHAR) by 32.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,435 shares of the company’s stock after purchasing an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 as of its most recent SEC filing. 0.03% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research report on Thursday, August 1st.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.